A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Hydrocodone IR is under clinical development by Elysium Therapeutics and currently in Phase I for Opium (Opioid) Addiction.

GH-002 is under clinical development by GH Research and currently in Phase I for Treatment Resistant Depression.

Fosravuconazole is under clinical development by Eisai and currently in Phase II for Tinea Pedis (Athlete Foot).

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

Glufosfamide is under clinical development by Eleison Pharmaceuticals and currently in Phase III for Metastatic Adenocarcinoma of The Pancreas.

Samelisant (SUVNG-3031) is under development for the treatment of narcolepsy with and without cataplexy and cognitive disorders. The drug candidate is administered orally in the form of tablet. The ...

EXT-608 is under clinical development by Extend Biosciences and currently in Phase II for Hypoparathyroidism. According to GlobalData, Phase II drugs for Hypoparathyroidism have a 60% phase transition ...

Crizanlizumab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

Fresolimumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer.